Parkway Life Real Estate Investment (C2PU) AI Stock Analysis

• Market Cap: S$2.62B
• Dividend Yield: 3.76%
• Average Volume (3M): 932.25K
• Price to Earnings (P/E): 17.2
• Beta (1Y): 0.27
• Revenue Growth: 2.55%
• EPS Growth: -23.99%
• Country: SG
• Employees: 23
• Sector: Real Estate
• Sector Strength: 53
• Industry: REIT - Healthcare Facilities
• EPS (TTM): 0.17
• Shares Outstanding: 652,653,140
• 10 Day Avg. Volume: 754,280
• 30 Day Avg. Volume: 932,253
• PEG Ratio: 0.40
• Price to Book (P/B): 1.59
• Price to Sales (P/S): 16.13
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: S$4.99
• Price Target Upside: 24.16% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): 0.18
• Revenue Forecast (FY): S$163.80M

• Rating: 64 Neutral
• Price Target: S$4.50 ▲(11.94% Upside)
• Action: Reiterated Date: 02/03/26
• Date: Action: Reiterated 02/03/26

The score is driven primarily by solid financial performance (re-accelerating revenue growth, moderate leverage, and stable operating cash flow), tempered by inconsistent free cash flow including a reported zero in 2025. Technical indicators are weak/neutral, while valuation is supportive but not compelling enough to offset the cash generation risk.

Positive Factors

Stable rental income from healthcare leases

Concentration in income-producing healthcare properties with long-term leases creates durable, contractually backed cash flows that are defensive versus economic cycles. That predictability supports steady distributions and planning for acquisitions or portfolio maintenance over the medium term.

Re-accelerating revenue growth

A renewed revenue acceleration indicates resilient tenant demand and/or effective portfolio expansion and rent escalation mechanics. Sustained top-line growth improves coverage of fixed costs and interest, enhancing distribution sustainability and strategic flexibility over the next several quarters.

Moderate leverage and growing equity base

Debt levels are moderate for a healthcare REIT and equity growth has bolstered the balance sheet, improving financial stability. This capacity supports measured accretive acquisitions, liquidity for capital needs, and resilience to interest rate variability compared with highly levered peers.

Negative Factors

Inconsistent free cash flow

Volatile or absent free cash flow undermines the REIT's ability to self-fund distributions, capex and acquisitions without external financing. A zero FCF year raises structural questions about discretionary cash available after maintenance and financing, increasing reliance on capital markets.

Volatile earnings quality

Material swings in reported profits and one-off items reduce the reliability of earnings as a guide to underlying cash generation. That volatility complicates forecasting distribution coverage, investor confidence, and could mask operational or accounting drivers that are not repeatable.

Weakened cash conversion and margin pressure

Lower cash conversion and softer EBIT despite higher revenue suggest rising operating costs or timing differences are compressing usable cash. Reduced conversion from accounting profits to cash limits reinvestment and increases distribution risk, necessitating closer scrutiny of cost trends and capital spending.

Parkway Life Real Estate Investment Business Overview & Revenue Model

Company Description

Parkway Life Real Estate Investment Trust ("PLife REIT") is one of Asia's largest listed healthcare REITs by asset size. It invests in income-producing real estate and real estate related assets that are used primarily for healthcare and healthcare-related purposes (including but are not limited to, hospitals, healthcare facilities and real estate and/or real estate assets used in connection with healthcare research, education, and the manufacture or storage of drugs, medicine and other healthcare goods and devices). PLife REIT owns a well-diversified portfolio of 54 properties located in the Asia Pacific region, with a total portfolio size of approximately S$2.02 billion3 as at 31 December 2020. It owns the largest portfolio of strategically-located private hospitals in Singapore comprising Mount Elizabeth Hospital, Gleneagles Hospital and Parkway East Hospital. In addition, it has 50 assets of high quality nursing home and care facility properties in various prefectures of Japan. It also owns strata-titled units/lots in MOB Specialist Clinics Kuala Lumpur in Malaysia.

How the Company Makes Money

Parkway Life Real Estate Investment generates revenue primarily through rental income from its portfolio of healthcare properties. The company leases its properties to operators of healthcare facilities, who pay rent on a long-term basis, ensuring a steady cash flow. Additionally, Parkway Life REIT benefits from the appreciation of property values over time, which can lead to capital gains upon the sale of assets. The company may also explore strategic partnerships with healthcare operators and developers, further enhancing its revenue opportunities. Furthermore, Parkway Life REIT may receive management fees and other income from its investment services, contributing to its overall earnings.

Parkway Life Real Estate Investment Financial Statement Overview

Summary

Solid overall fundamentals: revenue growth re-accelerated in 2025 (+9.2%), leverage is moderate for a REIT with growing equity, and operating cash flow has been stable. Offsetting this, earnings quality appears volatile and free cash flow has been inconsistent, including a reported zero in 2025, which raises concern around cash flexibility.

Income Statement

Revenue growth has been positive overall, accelerating in 2025 (+9.2%) after a small decline in 2024, indicating steady demand and a resilient rental base. Profitability appears very strong in 2023–2024 with high margins, though earnings quality looks volatile across the period (notably an unusually high profit year in 2021), suggesting reported net income may be influenced by non-recurring items. EBIT was also slightly softer in 2025 versus 2024 despite higher revenue, pointing to some cost pressure or normalization.

Balance Sheet

Leverage looks moderate for a REIT, with debt-to-equity generally in the ~0.56–0.67 range (2023–2024), and equity has grown over time, supporting balance sheet stability. Total debt has been broadly steady while assets and equity have increased, which is constructive. Return on equity has been inconsistent (low-to-mid single digits in 2022–2024 with a spike in 2021), indicating uneven profitability relative to the capital base.

Cash Flow

Operating cash flow has been relatively stable (roughly mid-$90M to ~$109M across 2020–2024), which is a positive for a defensive healthcare REIT profile. However, free cash flow has been volatile—strong in 2023 but meaningfully lower in 2022 and 2024—and 2025 free cash flow is reported as zero, creating uncertainty around current cash generation after capital needs. Cash conversion also weakened in 2024 (free cash flow materially below net income), suggesting less of the accounting profit is showing up as discretionary cash.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	151.16M	164.99M	144.85M	147.47M	129.97M	120.70M
Gross Profit	141.43M	134.61M	126.74M	124.59M	107.52M	98.43M
EBITDA	0.00	130.82M	113.88M	121.20M	112.14M	100.01M
Net Income	83.67M	152.79M	95.04M	100.47M	41.14M	331.88M
Balance Sheet
Total Assets	2.62B	2.65B	2.55B	2.33B	2.34B	2.35B
Cash, Cash Equivalents and Short-Term Investments	49.04M	47.77M	29.47M	28.50M	40.01M	25.79M
Total Debt	927.48M	887.54M	886.11M	828.47M	851.89M	828.01M
Total Liabilities	1.03B	982.62M	981.20M	919.58M	931.66M	910.43M
Stockholders Equity	1.59B	1.67B	1.57B	1.41B	1.41B	1.43B
Cash Flow
Free Cash Flow	0.00	0.00	46.68M	77.65M	30.74M	78.17M
Operating Cash Flow	0.00	99.49M	95.79M	108.69M	94.63M	89.86M
Investing Cash Flow	0.00	-69.71M	-239.93M	-49.56M	-125.18M	-74.99M
Financing Cash Flow	0.00	-7.17M	147.35M	-67.92M	47.75M	-9.98M

Parkway Life Real Estate Investment Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:C2PU, the sentiment is Positive. The current price of 4.02 is below the 20-day moving average (MA) of 4.04, below the 50-day MA of 4.03, and above the 200-day MA of 4.00, indicating a bullish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 57.28 is Neutral, neither overbought nor oversold. The STOCH value of 68.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SG:C2PU.

Parkway Life Real Estate Investment Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TQ5	67 Neutral	S$4.16B	18.09	2.37%	4.02%	-18.20%	40.87%
Sector *	65 Neutral	$2.17B	12.19	3.79%	4.94%	3.15%	1.96%
C2PU	64 Neutral	S$2.62B	17.16	5.49%	3.76%	2.55%	-23.99%
T82U	62 Neutral	S$4.20B	26.20	-0.32%	4.55%	0.01%	-110.22%
TS0U	57 Neutral	S$2.04B	77.08	-2.15%	6.03%	-11.65%	-137.98%
9A4U	46 Neutral	S$2.01B	355.71	-4.88%	7.91%	10.51%	-40.93%

Parkway Life Real Estate Investment Corporate Events

Parkway Life REIT Issues New Units for Management Fee Payment

Parkway Trust Management Limited, the manager of Parkway Life Real Estate Investment Trust, has announced the issuance of 33,901 new units to itself as part payment for management fees. These units, priced at approximately S$4.11 each, cover the base fee for the period from July to September 2025. This issuance increases the total number of units to 652,486,974, with the manager holding 1,462,774 units. This move reflects the company’s strategy to manage its financial obligations through equity, potentially impacting its market positioning and stakeholder interests.

The most recent analyst rating on (SG:C2PU) stock is a Buy with a S$4.97 price target. To see the full list of analyst forecasts on Parkway Life Real Estate Investment stock, see the SG:C2PU Stock Forecast page.

Parkway Life REIT Streamlines Structure with Subsidiary Dissolution

Parkway Life Real Estate Investment Trust has dissolved four of its wholly-owned subsidiaries in France as part of an internal restructuring to streamline its group holding structure. This dissolution is not expected to materially impact the net tangible assets or distributions per unit for the financial year ending 31 December 2025.

The most recent analyst rating on (SG:C2PU) stock is a Buy with a S$4.97 price target. To see the full list of analyst forecasts on Parkway Life Real Estate Investment stock, see the SG:C2PU Stock Forecast page.